Impact of Ex Vivo Lung Perfusion on Inpatient Cost: A Propensity Score‐Matched Analysis of the US Nationwide Healthcare Cost and Utilization Project Database

Authors:

Abstract
Background: The goal of this study was to investigate the association between ex vivo lung perfusion (EVLP) use and inpatient hospitalization cost for lung transplantation in a nationwide sample.Methods: Lung transplantation patients in 2018–2020 Nationwide Readmissions Database (NRD) were grouped based on use of EVLP. The primary outcome was total inpatient hospitalization cost. 1:2 propensity score matching by EVLP status was performed followed by multivariable linear regression to determine the association between inpatient cost and EVLP while adjusting for pre‐transplant hospital days, high volume EVLP center status, and propensity score.Results: There were 3902 lung transplants and 118 (3%) were recipients of EVLP lungs. Among EVLP patients, the median cost was $871 468 (IQR: $608 671–1 274 392), compared to $846 516 (IQR: $531 462–1 439 267, p = 0.871) among the total non‐EVLP cohort. After 1:2 propensity score‐matched cohort, recipients of EVLP lungs had longer median hospital length of stay (p = 0.046). In the multivariable model using the matched sample, increased cost was not associated with EVLP use (p = 0.783); however, high volume EVLP centers were associated with decreased cost (p = 0.018).Conclusions: EVLP use was not associated with greater inpatient costs and may be favorable at high volume centers.
Funding Information
  • National Center for Advancing Translational Sciences (UL1TR001855, UL1TR000130)

This publication has 14 references indexed in Scilit: